

Appointment and Resignation of Company Secretary and Change to Registered Office

Melbourne, Australia, 3 February 2015

Prescient Therapeutics Limited ("Prescient" or "the Company") is pleased to announce the appointment of Ms Melanie Leydin as Company Secretary of the Company effective this day. Melanie is a Chartered Accountant with 20 years' experience and an extensive background with ASX Listed entities. She is Principal of Leydin Freyer Corp Pty Ltd which provides Company Secretarial and Accounting services to a number of Companies within the Biotechnology and Resources sectors.

The Company further advises of a change to its registered office and contact details as follows:

Level 4,
100 Albert Road
South Melbourne
Victoria, 3205

Phone Number: +61 (0) 3 9692 7222
Fax Number: +61 (0) 3 9077 9233

The Company advises that Mr Sean Henbury has tendered his resignation as Company Secretary effective this day. The Board wishes to thank Mr Henbury for his efforts with all aspects of the Company and wishes him the best for his future endeavours.

Ends.

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company currently engaged in the development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound PTX-100 (GGTI-2418) for the treatment of multiple myeloma, breast and pancreatic cancer. PTX-100 is expected to enter Phase 1b/2 clinical trials in multiple myeloma and breast cancer in 2015.

Prescient Therapeutics has acquired oncology company AKTivate and its novel PTX-200 (TCN-P) cancer drug. The company's technology inhibits the highly promising drug target AKT and includes two active clinical trials – a Phase 1b/2 in breast cancer and an active Phase 1b in ovarian cancer. These trials are funded by US government authorities including grants from the Department of Defence and National Cancer Institute.

In addition, the company has granted a license to major French biotechnology company Transgene for access to its Co-X-GenTM technology for use in two of Transgene's immunotherapeutic products.

Contact:

Ms Melanie Leydin
Company Secretary
Ph: +61 (0) 3 9692 7222